-
- Joseph Longo
- 1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
-
- Jenna E. van Leeuwen
- 1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
-
- Mohamad Elbaz
- 1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
-
- Emily Branchard
- 1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
-
- Linda Z. Penn
- 1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
抄録
<jats:title>Abstract</jats:title><jats:p>Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate metabolic pathway. Multiple lines of evidence indicate that certain cancers depend on the mevalonate pathway for growth and survival, and, therefore, are vulnerable to statin therapy. However, these immediately available, well-tolerated, and inexpensive drugs have yet to be successfully repurposed and integrated into cancer patient care. In this review, we highlight recent advances and outline important considerations for advancing statins to clinical trials in oncology.</jats:p>
収録刊行物
-
- Clinical Cancer Research
-
Clinical Cancer Research 26 (22), 5791-5800, 2020-11-13
American Association for Cancer Research (AACR)
